Hengrui PD-1 nasopharyngeal carcinoma indication approved
Hengrui's 2020 financial report: revenue of 27.7 billion oncology drugs contributes 55% and PD-1 triples!
Kangfang Bio-PD-1/CTLA-4 Dual Antibody Approved Global Phase 3 Clinical First-line Treatment for Advanced Cervical Cancer
The PD-1 antibody purchased by GSK for US$5.1 billion was approved for listing in the U.S. and EU at the same time | Yimai Meng broke the news
FDA accelerates approval of GlaxoSmithKline PD-1 antibody to treat patients with specific endometrial cancer
GlaxoSmithKline’s PD-1 is approved for the treatment of endometrial cancer, differentiated competition to seize the market
Reactivate the immune response of PD-1 refractory patients!
Nature Cancer: EZH2 inhibitor + PD-1 inhibitor to enhance the therapeutic effect of prostate cancer
Hengrui PD-1 nasopharyngeal carcinoma indication is about to be approved
Fuhong Henlius PD-1 is reported to be listed for priority review!
; PD-1/CTLA-4 dual antibody was approved to carry out a phase III clinical trial for the first-line treatment of advanced cervical cancer|Tumor News
PD-L1 positive triple negative breast cancer (TNBC) immunotherapy!
Kangfang Bio-PD-1/CTLA-4 was approved to start a global phase 3 clinical trial for the treatment of cervical cancer
The potential of PD-1/PD-L1 neoadjuvant therapy is gradually showing. Who will become the first "dark horse" in China?
How safe is the new PD-L1 Nanobody "Xiaowo"?
The market demand cannot hold up to 84 PD-1/L1 products, what will the latecomers survive?
The first phase III study of Bristol-Myers Squibb PD-1+LAG-3 combination therapy is successful
The BD strategy behind the PD-1 business war
Hengrui's 2020 financial report: revenue of 27.7 billion oncology drugs contributes 55% of PD...
PD-1 immunotherapy drug Tuoyi® urothelial cancer indication approved in China